COMMUNIQUÉS West-GlobeNewswire

-
Chromocell to Present at Sidoti Virtual Investor Conference March 13-14
11/03/2024 -
Novo Nordisk A/S - share repurchase programme
11/03/2024 -
Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting
11/03/2024 -
CenTrak Unveils the Industry’s First BLE Multi-Mode Platform for RTLS at HIMSS 2024
11/03/2024 -
Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization
11/03/2024 -
Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million
11/03/2024 -
Intelligent Bio Solutions Announces $10.1 Million Private Placement Priced At-the-Market Under Nasdaq Rules
11/03/2024 -
Integra LifeSciences Launches MicroMatrix® Flex to Provide Convenient Access to Hard-to-Reach Areas in Complex Cases
11/03/2024 -
Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers
11/03/2024 -
NAPIGEN, Inc. Secures U.S. Patent, Awarded USDA SBIR Grant
11/03/2024 -
Allyx Therapeutics Announces Positive Phase 1b Multiple Ascending Dose Data and Advances ALX-001 to Patients
11/03/2024 -
ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis
11/03/2024 -
Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting
11/03/2024 -
Reviva to Present at the UBS Virtual CNS Day
11/03/2024 -
Theriva™ Biologics to Participate in the BIO-Europe Spring Conference
11/03/2024 -
Hyku Biosciences, a Covalent Precision Medicine Company, Announces CEO Transition for its Next Phase of Growth
11/03/2024 -
Harvard Bioscience, Inc. to Participate in March 2024 Investor Conferences: Sidoti’s Small Cap Conference and KeyBanc’s Life Sciences & MedTech Conference
11/03/2024 -
Qu Biologics and TransBIOTech Awarded $450K Applied Research and Development Grant Funding
11/03/2024 -
Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors
11/03/2024
Pages